体育博彩

Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC
2025-02-13
Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC
Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC
2025-02-05
Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC
Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
2025-01-27
Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer Published in Nature Medicine
2025-01-23
Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer Published in Nature Medicine
Akeso’s Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian Conference on Lung Cancer
2024-12-04
Akeso’s Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian Conference on Lung Cancer
Akeso to Present at Citi 2024 Global Healthcare Conference and the 7th Annual Evercore HealthCONx Conference
2024-11-29
Akeso to Present at Citi 2024 Global Healthcare Conference and the 7th Annual Evercore HealthCONx Conference
Akeso Announced the Inclusion in China’s National Reimbursement Drug List Of Cadonilimab and Ivonescimab
2024-11-28
Akeso Announced the Inclusion in China’s National Reimbursement Drug List Of Cadonilimab and Ivonescimab
Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA  
2024-11-22
Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA  
Akeso Biopharma to Attend Jefferies London Healthcare Conference and Morgan Stanley 23rd Asia Pacific Summit
2024-11-18
Akeso Biopharma to Attend Jefferies London Healthcare Conference and Morgan Stanley 23rd Asia Pacific Summit
Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting
2024-11-08
Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab
2024-11-01
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab
2024-10-31
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab
IM体育试玩 澳门银河博彩官方网站 博彩网址大全 bwin中文官网 正规博彩平台